Kenacort-T

Triamcinolone Acetonide, the active ingredient in Kenacort‑T, is a corticosteroid presented as an injectable formulation for intramuscular use. It is employed to reduce inflammation and modulate immune responses in various acute and chronic conditions.

GNH USA supplies Kenacort‑T as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kenacort‑T, a glucocorticoid, is used to manage inflammatory and immune‑mediated disorders.

- Allergic reactions: provides rapid relief of severe hypersensitivity symptoms. - Rheumatoid arthritis: reduces joint inflammation and pain during flare‑ups. - Musculoskeletal inflammation: alleviates pain and swelling in bursitis, tendinitis and similar conditions.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Injection site pain or irritation. - Elevated blood glucose levels. - Mild hypertension. - Insomnia or mood changes. - Increased appetite and weight gain. - Fluid retention or edema.

Serious or Rare Side Effects: - Adrenal suppression leading to cortisol deficiency. - Severe or opportunistic infections. - Osteonecrosis of the jaw or long bones. - Cushingoid appearance with skin thinning. - Psychosis or severe mood disorders. - Anaphylactic or severe hypersensitivity reactions.

Careful assessment and monitoring are essential when using Kenacort‑T.

- Infection risk: evaluate for active or latent infections before administration. - Blood glucose: monitor diabetic patients closely for hyperglycaemia. - Bone health: consider osteoporosis risk in long‑term or high‑dose therapy. - Dose minimisation: use the lowest effective dose for the shortest duration possible. - Contraindications: avoid in patients with systemic fungal infections. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Kenacort‑T may interact with several drug classes, requiring clinical judgement.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase systemic exposure. - Live vaccines: risk of inadequate immune response or infection. - Antidiabetic agents: may require dose adjustment due to hyperglycaemia. - NSAIDs: combined use raises gastrointestinal bleeding risk. - Anticoagulants: potential for enhanced anticoagulant effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin) may reduce efficacy. - Diuretics: possible electrolyte disturbances. - Antihypertensives: may blunt blood pressure control. - Non‑live vaccines: monitor immune response. - Herbal supplements (e.g., St John’s wort): may alter steroid metabolism.